Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interview: New Chugai CEO Lays Course As He Takes Reins (Part 2).

Executive Summary

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key new products reach the global market and others begin to face generic competition. In this second and final part of an exclusive interview with Scrip, he talks about major mid-term growth prospects, recent pricing reforms in Japan, and how Chugai is tapping into novel disruptive technologies. 

You may also be interested in...



Legal Challenge To First Japan Rituxan Biosimilar Dismissed

First Japan legal ruling means biosimilar competition can continue to gnaw away at Rituxan, at least for now, as Chugai faces rising challenges to its mature oncology portfolio.

Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain

The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.

Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain

The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel